MBC

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Retrieved on: 
Tuesday, March 5, 2024

Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this innovative immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events.

Key Points: 
  • Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this innovative immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events.
  • Additionally, all treatment-emergent adverse events during the safety observation period to date have been of mild severity.
  • The biologically active 30mg efti dose, previously the highest dose of efti ever tested, has demonstrated a stronger immune response and greater efficacy than lower dosing levels (1mg, 6mg) in multiple clinical trials.
  • The ongoing randomized Phase II portion of the trial, which will include up to 58 evaluable patients, is focused on whether 90mg efti dosing is safe and more efficacious than 30mg dosing.

New Study Addressing Global Concern for Breast Cancer Treatment Now Available in Clifton, N.J.

Retrieved on: 
Monday, March 4, 2024

A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.

Key Points: 
  • A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.
  • The SERENA-6 trial, sponsored by AstraZeneca, is a global study that aims to address a critical issue faced by many patients: their treatments become less effective over time.
  • In advanced breast cancer, patients receive a treatment that combines an estrogen-reducing drug with a drug that slows cancer cell growth.
  • This study will evaluate if an experimental trial drug, combined with a cancer-slowing drug, might work better than conventional estrogen-reducing drugs for patients with ESR1 mutations.

Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth

Retrieved on: 
Thursday, February 29, 2024

A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .

Key Points: 
  • A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .
  • “With the completion of the Seagen acquisition in 2023, Pfizer has significantly expanded its Oncology organization to amplify its efforts to advance new standards of care and improve outcomes for patients,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • Pfizer’s Oncology portfolio is focused on three core scientific modalities: small molecules, antibody drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics.
  • Please read full Prescribing Information , including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm).

MasterBrand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, February 26, 2024

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced fourth quarter and full year 2023 financial results.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced fourth quarter and full year 2023 financial results.
  • Net sales were $677.1 million, compared to $784.4 million in the fourth quarter of 2022, primarily due to lower volumes, driven by softer end-market demand.
  • Adjusted EBITDA1 was $85.8 million, compared to $97.8 million in the fourth quarter of 2022.
  • During the fourth quarter and full year 2023, the Company repurchased approximately 527 thousand shares of common stock and approximately 1.9 million shares of common stock, respectively.

Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website

Retrieved on: 
Monday, February 12, 2024

“Lasofoxifene, our lead investigational drug, has demonstrated both potential efficacy in combating metastatic breast cancer and potential benefit with respect to vaginal and sexual health.

Key Points: 
  • “Lasofoxifene, our lead investigational drug, has demonstrated both potential efficacy in combating metastatic breast cancer and potential benefit with respect to vaginal and sexual health.
  • The website and studies were named for Dr. Elaine Davidson Nemzer, the sister of Miriam Portman.
  • Davidson Nemzer was a brilliant and compassionate child psychiatrist whose life was cut short by mBC at the age of 47.
  • “It provides us with passion and purpose to help those suffering with metastatic breast cancer.”
    To learn more about Sermonix Pharmaceuticals and lasofoxifene, visit https://sermonixpharma.com .

Your Family Entertainment AG takes the next step and presses ahead with its international expansion

Retrieved on: 
Wednesday, February 7, 2024

Bernd Wendeln (COO Your Family Entertainment): "With these steps, we are further expanding our position as a global provider of children's and family entertainment.“

Key Points: 
  • Bernd Wendeln (COO Your Family Entertainment): "With these steps, we are further expanding our position as a global provider of children's and family entertainment.“
    Your Family Entertainment AG (“YFE”, WKN: A161N1, ISIN: DE000A161N14, ticker symbol: RTV), a leading children's and family entertainment company, announces the successful expansion of its global presence through cooperation agreements with two renowned international media companies.
  • Your Family Entertainment AG has further expanded its collaboration with MBC GROUP, the leading media company in the Middle East and North Africa.
  • Bernd Wendeln, COO of Your Family Entertainment AG: "The expansion of our partnerships with leading players in the MENA region and Mexico illustrates our continued commitment and success in making first-class, child-friendly entertainment accessible worldwide.
  • These steps further strengthen our position as a global provider of children's and family entertainment.

WEBINAR: Exploring the Impact of Measurement-Based Care at Homewood Health

Retrieved on: 
Thursday, January 25, 2024

Greenspace Health and Homewood Health are excited to present an educational event, Exploring the Impact of Measurement-Based Care at Homewood Health.

Key Points: 
  • Greenspace Health and Homewood Health are excited to present an educational event, Exploring the Impact of Measurement-Based Care at Homewood Health.
  • This session aims to share the clinical outcomes of Homewood Health’s Measurement-Based Care (MBC) implementation, along with key insights that have driven care quality improvements and innovation across their mental health services.
  • The session will provide a guiding framework for other mental health organizations implementing MBC, empowering them to provide the highest quality of care to the communities they serve.
  • Homewood Health’s implementation with Greenspace Health began in 2018.

Grant Thornton names Alley-Oop Kids as its new Purple Paladin

Retrieved on: 
Tuesday, January 23, 2024

In June of 2023, Grant Thornton also worked with another sports-related Purple Paladin, the I GOT THIS Foundation, which promotes golf instruction and playing opportunities for people with intellectual disabilities.

Key Points: 
  • In June of 2023, Grant Thornton also worked with another sports-related Purple Paladin, the I GOT THIS Foundation, which promotes golf instruction and playing opportunities for people with intellectual disabilities.
  • To learn more about Alley-Oop Kids, visit https://www.alleyoopkids.org/
    Alley-Oop Kids joins 17 other 501(c)(3) nonprofits that Grant Thornton previously selected as Purple Paladins.
  • Grant Thornton’s Purple Paladins program derives its name from the word paladin, a champion of a cause.
  • Grant Thornton and its professionals have donated more than $1 million to Purple Paladin nonprofits, and more than 650 Grant Thornton professionals have volunteered their time and skills to support the firm’s Purple Paladins.

MasterBrand to Announce Fourth Quarter and Full Year 2023 Results on February 26

Retrieved on: 
Wednesday, January 17, 2024

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced it will release its fourth quarter and full year 2023 financial results after the market close on Monday, February 26, 2024.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced it will release its fourth quarter and full year 2023 financial results after the market close on Monday, February 26, 2024.
  • The Company will hold a live conference call and webcast at 4:30 p.m.
  • ET the same day to discuss the financial results and business outlook.
  • The live audio webcast can be accessed on the “Investors” section of the MasterBrand website at www.masterbrand.com .

Susan G. Komen® Pushing for Public Policies to Eliminate Disparities in Breast Care Access

Retrieved on: 
Thursday, January 25, 2024

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, is committed to making health care more affordable and accessible to all, by passing state and federal legislation in 2024 to remove barriers that prevent people from receiving the timely and high-quality breast care they need.

Key Points: 
  • Public policies that remove ob­­­­­­stacles, such as the cost of care and when and where care is available, would make an immediate difference in mortality rates.
  • In fact, about one-third of breast cancer deaths could be prevented if everyone received the high-quality care that exists today.
  • Breast imaging, the most effective tool at detecting breast cancers, is available to most people yet is not accessible to all.
  • "Komen is approaching breast cancer comprehensively through diverse public policy initiatives, aiming to minimize the number of breast cancer deaths," Guthrie added.